Compare PEP & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEP | ABT |
|---|---|---|
| Founded | 1898 | 1888 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.7B | 222.8B |
| IPO Year | N/A | N/A |
| Metric | PEP | ABT |
|---|---|---|
| Price | $148.58 | $129.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $157.79 | $146.61 |
| AVG Volume (30 Days) | ★ 7.2M | 6.6M |
| Earning Date | 10-09-2025 | 10-15-2025 |
| Dividend Yield | ★ 3.83% | 1.83% |
| EPS Growth | N/A | ★ 141.97 |
| EPS | 5.26 | ★ 7.96 |
| Revenue | ★ $92,366,000,000.00 | $43,843,000,000.00 |
| Revenue This Year | $2.74 | $7.55 |
| Revenue Next Year | $3.37 | $7.70 |
| P/E Ratio | $28.29 | ★ $16.19 |
| Revenue Growth | 0.48 | ★ 6.37 |
| 52 Week Low | $127.60 | $110.86 |
| 52 Week High | $163.65 | $141.23 |
| Indicator | PEP | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 53.60 |
| Support Level | $144.76 | $126.23 |
| Resistance Level | $148.94 | $129.52 |
| Average True Range (ATR) | 2.23 | 2.72 |
| MACD | 0.27 | 0.31 |
| Stochastic Oscillator | 85.42 | 70.24 |
PepsiCo is a global leader in snacks and beverages, owning well-known household brands including Pepsi, Mountain Dew, Gatorade, Lay's, Cheetos, and Doritos, among others. The company dominates the global savory snacks market and also ranks as the second-largest beverage provider in the world (behind Coca-Cola) with diversified exposure to carbonated soft drinks, or CSD, as well as water, sports, and energy drink offerings. Convenience foods account for approximately 55% of its total revenue, with beverages making up the rest. Pepsi owns the bulk of its manufacturing and distribution capacity in the US, but uses bottlers overseas for beverages. International markets made up 40% of both total sales and operating profits in 2024.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.